MD FACC - Graphite Bio CEO Pres

GRPHDelisted Stock  USD 2.67  0.05  1.84%   

Insider

MD FACC is CEO Pres of Graphite Bio
Age 50
Phone650 484 0886
Webhttps://graphitebio.com

Graphite Bio Management Efficiency

The company has return on total asset (ROA) of (0.1799) % which means that it has lost $0.1799 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5195) %, meaning that it created substantial loss on money invested by shareholders. Graphite Bio's management efficiency ratios could be used to measure how well Graphite Bio manages its routine affairs as well as how well it operates its assets and liabilities.
Graphite Bio currently holds 362 K in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Graphite Bio has a current ratio of 26.53, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Graphite Bio's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Oleg NodelmanNuvation Bio
44
Christopher JDSensei Biotherapeutics
N/A
MD FACPNextCure
71
AO FRACPAssembly Biosciences
65
Kerry WentworthNuvation Bio
51
Bronson CrouchInstil Bio
51
Erin ColganSensei Biotherapeutics
43
David MDNuvation Bio
54
Tharaknath RaoAssembly Biosciences
N/A
CPA CPANextCure
61
Nicole WhiteAssembly Biosciences
N/A
BSc FRCPathAchilles Therapeutics PLC
59
Gary HattersleyNuvation Bio
57
Thomas TemplemanNuvation Bio
60
Sandeep MDInstil Bio
55
Iraj AliAchilles Therapeutics PLC
49
MBA BSCytomX Therapeutics
45
FMEDSCI MDAchilles Therapeutics PLC
49
Michele AndersonAssembly Biosciences
N/A
Steven FullerSensei Biotherapeutics
N/A
Adam ZlotnickAssembly Biosciences
N/A
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California. Graphite Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 111 people. Graphite Bio (GRPH) is traded on NASDAQ Exchange in USA and employs 6 people.

Management Performance

Graphite Bio Leadership Team

Elected by the shareholders, the Graphite Bio's board of directors comprises two types of representatives: Graphite Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Graphite. The board's role is to monitor Graphite Bio's management team and ensure that shareholders' interests are well served. Graphite Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Graphite Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
Stephanie Yao, Vice Relations
Maria MD, Academic Board
Christine PMP, Chief Operations
Jerry Cacia, Chief Officer
Philip Gutry, Chief Officer
Jane Grogan, Chief Officer
MD FACC, CEO Pres
Daniel Dever, CoFounder Research
Alethia Young, Chief Officer
Kimberlee CPA, CEO and Presidentident
Matthew MD, Academic Director

Graphite Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Graphite Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.

Other Consideration for investing in Graphite Stock

If you are still planning to invest in Graphite Bio check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Graphite Bio's history and understand the potential risks before investing.
Global Correlations
Find global opportunities by holding instruments from different markets
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Fundamental Analysis
View fundamental data based on most recent published financial statements
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity